Compound ID | 1279

Update compound information

NXL-105

Class: Cell-wall synthesis inhibitor (PBP2 inhibitor)

Spectrum of activity: Gram-negative
Details of activity: Activity against P. aeruginosa In Vitro
Institute where first reported: Entasis Therapeutics
Year first mentioned: 2019
Highest development stage: Preclinical
Development status: Inactive
Reason dropped: NXL-105 is not Efficacious against P. aeruginosa In Vivo
Chemical structure(s):
Click here for structure editor
Molecular weight: 303.3
Iso. SMILES: CN1C2=C(C=N1)[C@@H]3CN([C@@H]2CN)C(=O)N3OS(=O)(=O)O
InChI Key: RQBKZSHXCSVMSL-RQJHMYQMSA-N
Can. SMILES: CN1C2=C(C=N1)[C@@H]3CN([C@@H]2CN)C(=O)N3OS(=O)(=O)O
InChI: InChI=1S/C9H13N5O5S/c1-12-8-5(3-11-12)7-4-13(6(8)2-10)9(15)14(7)19-20(16,17)18/h3,6-7H,2,4,10H2,1H3,(H,16,17,18)/t6-,7+/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/146626473
Citation: http://www.entasistx.com/application/files/6415/5795/6549/PBP3NBP_Presentation__ECCMID_2019_Amsterdam_04082019_Thomas_Durand-Reville_FINAL.pdf

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.